Seattle

Umoja Biopharma Announces Participation in Upcoming Scientific Summits

Retrieved on: 
Thursday, June 30, 2022
Seattle, Inc., Patient, Engineering, GLOBE, Umoja, Industry, Therapy, CAR, Toxicity, Immunotherapy, Purdue University, Outline, Pharmaceutical industry, Online gambling, Vaccine

SEATTLE, June 30, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced today that the company will participate in two Hanson Wade summits taking place in July in Boston.

Key Points: 
  • SEATTLE, June 30, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced today that the company will participate in two Hanson Wade summits taking place in July in Boston.
  • Umoja Biopharma, Inc. is an early clinical-stage company advancing an entirely new approach to immunotherapy.
  • Umoja Biopharma, Inc. is a transformative multi-platform immuno-oncology company founded with the goal of creating curative treatments for solid and hematological malignancies by reprogramming immune cells in vivo to target and fight cancer.
  • Umoja believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives.

Umoja Biopharma Presents Data on its Engineered Induced Pluripotent Stem Cell Platform at the 2022 International Society for Stem Cell Research Annual Meeting

Retrieved on: 
Thursday, June 16, 2022
International Society for Stem Cell Research, Stem cell, Team leader, Therapy, Cytokine, Technology, Survival, Seattle, CAR, Purdue University, DNA, International Society, Iclingas, Patient, ISSCR, Cell, IPSC, Annual general meeting, GLOBE, Immunotherapy, Mobile phone, Vaccine, Umoja

The presentation will discuss Umojas engineered induced pluripotent stem cell (iPSC) platform, that incorporates the synthetic cytokine receptor system rapamycin-activated cytokine receptor (RACR) platform.

Key Points: 
  • The presentation will discuss Umojas engineered induced pluripotent stem cell (iPSC) platform, that incorporates the synthetic cytokine receptor system rapamycin-activated cytokine receptor (RACR) platform.
  • The RACR platform has the potential to enable cytokine-free manufacturing and engraftment of the engineered cells in the patient without the need for toxic lymphodepletion.
  • We are developing an engineered iPSC platform, including the RACR platform, to address these challenges by enabling a scalable, virtually unlimited, and simplified manufacturing of engineered, cancer-fighting cytotoxic innate lymphocytes.
  • Umoja Biopharma, Inc. is an early clinical-stage company advancing an entirely new approach to immunotherapy.

MobileSmith Appoints Joel French to Strategic Advisory Board

Retrieved on: 
Monday, June 13, 2022
Technology, Mobile, Wireless, Nursing, Hospitals, Software, Practice Management, Health, General Health, Data Management, IPad, Seattle, Caregiver, IPhone, SCI, BA, Pacific Lutheran University, LLC, Advisory board, OTCBB, CEO, Software, Organization, Nursing, Strategic Advisory Group of Experts, Physician, Android, Acquisition, Solution, Industry, RCM, Management, Healthcare, Economics

MobileSmith (OTCBB: MOST), a leading provider of cutting-edge mobile software solutions, announces the appointment of Joel French to their Strategic Advisory board.

Key Points: 
  • MobileSmith (OTCBB: MOST), a leading provider of cutting-edge mobile software solutions, announces the appointment of Joel French to their Strategic Advisory board.
  • Were thrilled that Joel is joining our Advisory Board.
  • Joels healthcare and company growth experience will be fundamental in helping MobileSmith Health navigate the healthcare ecosystem.
  • Implementing methods of retaining nurses, physicians, and other caregivers has become among the highest priorities for provider enterprise, said Joel French.

Umoja Biopharma and TreeFrog Therapeutics Announce Collaboration to Address Current Challenges Facing Ex Vivo Allogeneic Therapies in Immuno-Oncology

Retrieved on: 
Friday, June 10, 2022
Potency (pharmacology), Immunotherapy, Seattle, Cell, Purdue University, B cell, NK, GMP, IPS, Therapy, IPSC, Inc., GLOBE, Patient, Secondary research, Adoption, Fibroblast, Tree, Industry, Culture, Bioreactor, Cancer, Regenerative medicine, Vaccine, Umoja

Together, the successful pairing of Umojas RACR engineered iPS cells and TreeFrogs C-Stem technology could overcome several challenges facing ex vivo allogeneic therapies, said Ryan Larson, Ph.D., Vice President and Head of Translational Science at Umoja.

Key Points: 
  • Together, the successful pairing of Umojas RACR engineered iPS cells and TreeFrogs C-Stem technology could overcome several challenges facing ex vivo allogeneic therapies, said Ryan Larson, Ph.D., Vice President and Head of Translational Science at Umoja.
  • Two major industry-wide challenges include the ability to scale iPSC-based culture while maintaining cell health, quality, and efficient immune cell differentiation.
  • Besides scale-up and cell quality, the in vivo persistence of allogeneic therapies remains a critical challenge in the industry.
  • TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients.

Unity Care Announces Impressive Speaker Lineup for 3rd Annual Town Hall Focused on Improving Health Outcomes for Black and Latinx Youth

Retrieved on: 
Friday, June 3, 2022
FAAFP, National Football League, Silicon, NFL, Seattle Seahawks, AFL, COA, Reyes, Community organizing, Public, Medical director, COVID-19, Unity, Wellness, Medicine, History, Council, Town hall, Silicon Valley Community Foundation, Knowledge, MBA, TED (conference), Child, CEO, Partnership, Pastoral counseling, County, Town Hall, Health, Parent, MD, Industry, Spirituality, Town, Mental health, Organization, Juneteenth, Family, University, PST, ASL, Stanford University, Root, Exercise, Life, Program, Seattle, Food, Black Europeans of African ancestry, GLOBE, University of Washington Department of Global Health, Promotora, Color, Management, Accreditation, Central Coast, SAN

on Zoom with a welcome speech from event moderator Janice Edwards, an Emmy-nominated and award-winning talk show host, producer and author.

Key Points: 
  • on Zoom with a welcome speech from event moderator Janice Edwards, an Emmy-nominated and award-winning talk show host, producer and author.
  • She pioneered the provision of a community-based, community-driven and community-empowering model for improving wellness, called Whole Health.
  • Covid-19 Black strives to eliminate the spread of Covid-19 and improve overall health outcomes in the African Ancestry community.
  • The third annual virtual COVID-19 Black town hall is being organized largely in partnership with Walden Family Services.

Umoja Biopharma and Lupagen Announce New Collaboration to Improve Patient Experience and Access to Next-Generation In Vivo Therapeutics for Cancer

Retrieved on: 
Monday, May 23, 2022
Company, Immunotherapy, Patient, Hematological Cancer Research Investment and Education Act, Health, Gene editing, COVID-19, Research, Hope, Social disruption, Partnership, Purdue University, Side, Seattle, Technology, Neoplasm, Drug development, Therapy, Umoja, GLOBE, Vaccine, Pharmaceutical industry, DALLAS

Todays cellular therapies are often hampered by lengthy delays to patient treatment with a weeks-to-months wait for cell manufacturing and release.

Key Points: 
  • Todays cellular therapies are often hampered by lengthy delays to patient treatment with a weeks-to-months wait for cell manufacturing and release.
  • This partnership seeks to transform patient care by pairing Lupagens novel extracorporeal gene delivery technology with Umojas next-generation in vivo therapeutics to revolutionize cancer treatment.
  • Umoja Biopharma, Inc., is developing treatments for solid tumors and hematologic cancers that reprogram the patients immune system in vivo.
  • Umoja believes its approach can broaden access to advanced immunotherapies to give more patients the hope of lasting remission.

Umoja Biopharma Presents New Preclinical Data at ASGCT 2022 Annual Meeting on its VivoVec Platform Describing Preclinical Safety Data for UB-VV100 Product Candidate, VivoVec Engineering for Improved in vivo CAR T cell Generation and Development of a Scala

Retrieved on: 
Thursday, May 19, 2022
Therapy, Company, Annual general meeting, Toxicology, Patient, Â, Poster, Hematological Cancer Research Investment and Education Act, Intranodal palisaded myofibroblastoma, Society, CGMP, COVID-19, Research, Hope, Gene, Mouse, Efficiency, Social disruption, Purdue University, Engineering, Seattle, Safety, Neoplasm, Drug development, American Society of Gene and Cell Therapy, Cell, CAR, Lymph, GLOBE, Vaccine, Umoja

SEATTLE, May 19, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with solid and hematologic malignancies, announced data from three presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on its scalable, off-the-shelf in vivo lentiviral vector-based platform, termed VivoVec, that has the potential to achieve efficient T cell transduction upon direct administration to patients.

Key Points: 
  • Umojas one oral and two poster presentations demonstrate progress in UB-VV100 IND-enabling studies, manufacturing platform development, and next generation VivoVec surface engineering.
  • Preclinical data provides early evidence of the anti-tumor activity and preliminary preclinical safety of UB-VV100, Umojas preclinical candidate for the treatment of B cell malignancies.
  • Umoja further describes a scalable, suspension cell culture-based manufacturing process capable of producing cGMP-grade lentiviral vector product for in vivo CAR T cell therapy.
  • Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Umoja Biopharma Announces Resignation of Board Chair Clay B. Siegall

Retrieved on: 
Wednesday, May 11, 2022
Company, Blood, Patient, Hematological Cancer Research Investment and Education Act, Matthew Scharenberg, COVID-19, Research, Hope, Social disruption, Purdue University, Board, Seattle, Neoplasm, Drug development, Umoja, Chairperson, GLOBE

SEATTLE, May 11, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. announced today Clay B. Siegall, Ph.D. agreed to the Companys request to resign from Umojas board of directors, effective immediately.

Key Points: 
  • SEATTLE, May 11, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. announced today Clay B. Siegall, Ph.D. agreed to the Companys request to resign from Umojas board of directors, effective immediately.
  • Scharenberg assumes the role of interim Board Chair.
  • Umoja Biopharma, Inc., is developing treatments for solid tumors and hematologic cancers that reprogram the patients immune system in vivo.
  • This press release contains forward-looking statements about Umoja Biopharma, Inc. (the Company, we, us, or our).

Umoja Biopharma Presents Data on its Synthetic Cytokine Receptor Platform at the International Society for Cell and Gene Therapy Annual Meeting 2022

Retrieved on: 
Wednesday, May 4, 2022
Social disruption, Hope, COVID-19, Drug development, Population, Hematological Cancer Research Investment and Education Act, GLOBE, Company, Cell, Seattle, IPSC, Doctor of Philosophy, Patient, ISCB Senior Scientist Award, ISCT, Gene, Survival, Neoplasm, Therapy, Iclingas, Potency (pharmacology), Fibroblast, Technology, Purdue University, Research, International Society, Vaccine, Umoja

On Friday, May 6th, Dave Vereide, Ph.D., Senior Scientist at Umoja Biopharma,will give an oral presentation titled A synthetic cytokine receptor platform for producing cytotoxic innate lymphocytes as off-the-shelf cancer therapeutics.

Key Points: 
  • On Friday, May 6th, Dave Vereide, Ph.D., Senior Scientist at Umoja Biopharma,will give an oral presentation titled A synthetic cytokine receptor platform for producing cytotoxic innate lymphocytes as off-the-shelf cancer therapeutics.
  • The presentation will highlight Umojas rapamycin-activated cytokine receptor (RACR) platform which seeks to address current challenges in the cellular therapy space.
  • A synthetic small molecule ligand then binds RACR to drive the differentiation and expansion of the iCILs.
  • Umoja Biopharma, Inc., is developing treatments for solid tumors and hematologic cancers that reprogram the patients immune system in vivo.

Umoja Biopharma Announces Activation of First ENLIGHTen Phase 1 Trial Site in Study of UB-TT170, a TumorTag that Targets Folate Receptors to Mark Tumors for Clearance by CAR T Cells

Retrieved on: 
Tuesday, May 3, 2022
Child, Statistics, COVID-19, Hope, Drug development, Hematological Cancer Research Investment and Education Act, IND, Seattle Children's, Health, GLOBE, Clinical Cancer Research, Company, Neoplasm, Enlightenment, Osteosarcoma, Seattle, Safety, Food, CAR, Adolescence, OS, U.S. News & World Report, Patient, Umoja, Foundation, Partnership, Clinical trial, FDA, Cancer, Hospital, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, UB, PMID, Social disruption, Ageing, Prognosis, Neuroscience, Fluorescein, News, Infection, Survival rate, Purdue University, Research, Sarcoma, Nursing care plan, Pharmaceutical industry, Medical imaging, Vaccine

We are excited to receive IND clearance of our first TumorTag product candidate UB-TT170, said Andy Scharenberg, M.D., co-founder and Chief Executive Officer of Umoja Biopharma.

Key Points: 
  • We are excited to receive IND clearance of our first TumorTag product candidate UB-TT170, said Andy Scharenberg, M.D., co-founder and Chief Executive Officer of Umoja Biopharma.
  • The ability to target solid tumors with CAR T technology remains a large barrier for patients with cancer.
  • The ENLIGHTen trial ( NCT05312411 ) is an open-label Phase 1 feasibility and safety study of fluorescein-specific CAR T cells in combination with folate-fluorescein (UB-TT170) for patients with refractory/recurrent osteogenic sarcoma.
  • The primary endpoint is safety (adverse events tracking) with secondary endpoints focused on the ability to manufacture anti-fluorescein CAR T cells.